$TBRIF Therma Bright Submits AcuVid(TM) COVID-19 R
Post# of 99241
(Total Views: 144)
Posted On: 03/29/2022 1:56:58 PM
$TBRIF Therma Bright Submits AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Application for U.S. Food & Drug Administration's Emergency Use Authorization (EUA)
https://www.newsfilecorp.com/release/118493
Toronto, Ontario--(Newsfile Corp. - March 29, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"
, developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the submission of its U.S. Food & Drug Administration's (FDA) Emergency Use Authorization (EUA) application for its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test for Point of Care (POC).
"I am pleased to announce the submission of our AcuVid™ COVID-19 Rapid Antigen Saliva Test for U.S. Food & Drug Administration's Emergency Use Authorization," shared Rob Fia, CEO of Therma Bright. "Our application includes data from our U.S. clinical performance study, Brazilian clinical study, all required cross-reactivity tests, additional FDA requested cross-reactivity tests for mouth-borne viruses and bacteria, and numerous tests around World Health Organization's (WHO) Variants of Concern (VOCs), such as Delta and Omicron. Our team and partners stand ready to deliver upon receipt of FDA EUA."
Since July 2021, the Company's Executive and Development teams have worked with FDA officials, doctors and scientists on its AcuVid™ EUA application requirements. Timing on this authorization process is unknown, therefore, the Company will only notify the market upon receipt of the FDA's decision.
"With our AcuVid™ FDA EUA application submitted, the Company has begun investigating another saliva-based testing technology incorporating a robust platform for the detection for other respiratory infectious diseases affecting the lungs, as well as a novel saliva-based platform for Neuro-Vascular disorders (e.g. PTSD, head trauma/concussion)," continued Rob Fia, Therma Bright's CEO. "We'll keep the market updated on this effort, along with our business progress on our other medical devices."
Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.
https://www.newsfilecorp.com/release/118493
Toronto, Ontario--(Newsfile Corp. - March 29, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"
, developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the submission of its U.S. Food & Drug Administration's (FDA) Emergency Use Authorization (EUA) application for its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test for Point of Care (POC). "I am pleased to announce the submission of our AcuVid™ COVID-19 Rapid Antigen Saliva Test for U.S. Food & Drug Administration's Emergency Use Authorization," shared Rob Fia, CEO of Therma Bright. "Our application includes data from our U.S. clinical performance study, Brazilian clinical study, all required cross-reactivity tests, additional FDA requested cross-reactivity tests for mouth-borne viruses and bacteria, and numerous tests around World Health Organization's (WHO) Variants of Concern (VOCs), such as Delta and Omicron. Our team and partners stand ready to deliver upon receipt of FDA EUA."
Since July 2021, the Company's Executive and Development teams have worked with FDA officials, doctors and scientists on its AcuVid™ EUA application requirements. Timing on this authorization process is unknown, therefore, the Company will only notify the market upon receipt of the FDA's decision.
"With our AcuVid™ FDA EUA application submitted, the Company has begun investigating another saliva-based testing technology incorporating a robust platform for the detection for other respiratory infectious diseases affecting the lungs, as well as a novel saliva-based platform for Neuro-Vascular disorders (e.g. PTSD, head trauma/concussion)," continued Rob Fia, Therma Bright's CEO. "We'll keep the market updated on this effort, along with our business progress on our other medical devices."
Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.
(0)
(0)